QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access (TRA)

Coronary Artery Disease Clinical Trial

Official title:

A Randomized Comparison of the QuikClot® Radial® Pad Versus the Standard of Care TR Band® on Hemostasis After Transradial Artery Access (TRA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03535597
• Other study ID #: QuikClot300
• Status: Completed
• Phase: N/A
• Start date: August 1, 2018
• Est. completion date: December 28, 2022

Study information

• Verified date: January 2023
• Source: Memorial Healthcare System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of the QuikClot® Radial® pad on hemostasis after TRA, compared to the standard of care TR Band®, with the goal to hopefully develop a safe and efficacious technique to achieve more rapid patent hemostasis after TRA, and improve patient care by optimizing radial hemostasis management.

Description:

The QuikClot® Radial® pad will be applied over the radial artery access site covered with either a Coban™ bandage or a Tegaderm™ dressing after TRA. Firm manual compression will then be applied over the QuikClot® Radial® pad after the sheath is removed for 5 minutes. The Coban™ cohort will then have the Coban™ bandage removed after an additional 25 minutes, then be covered with a Tegaderm™ dressing. The Tegaderm™ only cohort will be closely observed for 25 minutes after release of manual pressure. Both cohorts will remove the Tegaderm™ dressing the following morning.

Consented subjects will be randomly assigned in the cardiac cath lab upon completion of their procedure into the following three arms:

Arm 1 - Standard of Care with a TR Band® Arm 2 - QuikClot® Radial® pad combined with a Coban™ bandage Arm 3 - QuikClot® Radial® pad combined with a Tegaderm™ dressing

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: December 28, 2022
• Est. primary completion date: December 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients undergoing CC and/or PCI via the radial artery as part of their standard of care treatment

2. Patients able and willing to give written informed consent

3. Patient > 18 years of age

Exclusion Criteria:

1. Patients presenting with acute ST segment elevation myocardial infarction (STEMI)

2. Oral anticoagulation therapy as described below:

1. If on a DOAC (direct acting oral anticoagulants - ie dabigatran, rivaroxaban, apixaban, endoxaban), patients will be excluded if DOAC taken within 48 hours and eGFR > 30 ml/min or DOAC taken within 72 hours and eGFR < 30 ml/min.

2. If patient is on warfarin, excluded if INR > 1.5

3. Liver Failure

4. Life threatening illness that patient would not be expected to live more than 6 months post procedure

5. Major unanticipated event in the cardiac cath lab (i.e. cardiac arrest) of an already consented patient, but before randomization, where the operator believes participation in this trial is now inappropriate.

6. Thrombocytopenia, with a platelet count of < 75,000.

Related Conditions & MeSH terms

• Coronary Artery Disease

Intervention

Device:
• Quikclot Radial Pad
The QuikClot® Radial® pad will be applied over the radial artery access site covered with either a Coban™ bandage or a Tegaderm™ dressing after TRA.

Locations

Country	Name	City	State
United States	Memorial Healthcare System	Hollywood	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Healthcare System	Z-Medica

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Initial successful hemostasis	Initial successful hemostasis is defined as no evidence of external bleeding from the TRA puncture site or expanding hematoma of the forearm after completion of the above described TR Band® and QuikClot® Radial® pad protocols, without the need for reinflation of air in the TR Band® or reapplication of manual pressure over the QuikClot® Radial® pad secured with either a Coban™ bandage or Tegaderm™ dressing, or use of manual compression over the arteriotomy site.	3 hours
Primary	Total Time to hemostasis	Total time to hemostasis will be calculated as the time needed from sheath removal to achieving complete hemostasis, as described below: For both the QuikClot® Radial® pad + Coban™ bandage and the QuikClot® Radial® pad + Tegaderm™ dressing arms, total time to hemostasis includes the initial 5 minutes of manual compression and 25 minutes of light compression with the Coban™ bandage in the Coban™ cohort and 5 minutes of manual compression and 25 minutes of close observation in the Tegaderm™ only cohort, and any subsequent time needed to obtain complete hemostasis. All additional protocol directed recompression and/or weaning times needed to obtain complete hemostasis will be added to calculate the total time to hemostasis.; For the standard of care TR Band® arm, total time to hemostasis includes the initial 60 minutes of compression plus 60 minutes of weaning, plus any additional protocol directed recompression and/or weaning time needed to obtain complete hemostasis.	3 hours
Secondary	Radial Artery Occlusion	RAO will be assessed one hour after completed hemostasis, using the reverse Barbeau's test.	1 hour